Turmeric compound tested as eye scanner for Alzheimer's

NCT ID NCT05774704

Recruiting now Knowledge-focused Sponsor: Texas Tech University Health Sciences Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing whether taking curcumin (the active ingredient in turmeric) for two weeks can cross into the brain and attach to amyloid beta proteins, which are linked to Alzheimer's disease. Researchers will use eye imaging to detect these proteins and also check how curcumin affects the gut microbiome. The study involves 60 adults aged 40-89 who have amyloid deposits in their retina.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: curcumin
What this could lead to: If successful, this could point toward a way to detect or monitor Alzheimer's disease using a simple eye test.
What could go wrong: This is a very early, small pilot study (60 people) testing feasibility, not effectiveness. Curcumin is poorly absorbed, and results may not lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOAVAILABILITY GUT MICROBIOME SAFETY

Contacts and locations

Locations

Texas Tech University Health Sciences Center
RECRUITING

Lubbock, Texas, 79430, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.